Tori Rodriguez, MA, LPC, AHC

Contributing Writer

Tori Rodriguez, MA, LPC, AHC, is an Atlanta-based journalist, licensed psychotherapist, and Ayurvedic health coach, creator of the body-positive wellness company Bettie Page Fitness, and author of 2 books – The Little Book of Bettie: Taking a Page from the Queen of Pinups and Bettie Page: The Lost Years. She holds a BS in psychology from Georgia State University and an MA in counseling psychology from the Georgia School of Professional Psychology. Tori has also managed a medical practice and was instrumental in developing Georgia’s multispecialty telemedicine program. Photograph courtesy of Brooklyn Brat Images.

All articles by Tori Rodriguez, MA, LPC, AHC

Pediatric Cancer

Psychiatric Disorders in Pediatric, AYA Cancer Survivors: Impact of Treatment

Tori Rodriguez, MA, LPC, AHC

February 9, 2022

Cancer treatment may have the greatest impact on psychological functioning in pediatric and adolescent/young adult cancer survivors.

Pediatric Cancer

Psychiatric Disorders in Pediatric, AYA Cancer Survivors: Risk Prediction and Screening

Tori Rodriguez, MA, LPC, AHC

February 8, 2022

Survivors of pediatric and adolescent/young adult cancers have an increased risk of mental health disorders that may persist for years.

General Oncology

Team Discovers ‘Spin’ in Most Reports of Noninferiority Cancer Trials

Tori Rodriguez, MA, LPC, AHC

December 28, 2021

Researchers identified misleading reporting in 75% of trials.

Gastrointestinal Cancers

Are Immune Checkpoint Inhibitors Better Than Standard Care for Unresectable HCC?

Tori Rodriguez, MA, LPC, AHC

December 22, 2021

Patients who received immune checkpoint inhibitors had better overall and progression-free survival.

Doctor using stethoscope on older female patient.

Breast Cancer

Cardiovascular Disease in Breast Cancer: Better Preventative Strategies Needed

Tori Rodriguez, MA, LPC, AHC

December 21, 2021

Cardiovascular disease remains a leading cause of death among breast cancer survivors.

Endocrine Cancer

Adding Monoclonal Antibody to Induction Could Be New Standard Care for High-Risk Neuroblastoma

Tori Rodriguez, MA, LPC, AHC

December 17, 2021

Results from a phase 2 trial, if validated in a larger study, may be practice-changing, according to researchers.

Hematologic Cancers

Study Reveals ‘Best Biomarker to Date’ for Predicting Relapse After CAR T-Cell Therapy

Tori Rodriguez, MA, LPC, AHC

December 16, 2021

Minimal residual disease in the bone marrow, detected via next-generation sequencing, was “highly predictive” of relapse after treatment with tisagenlecleucel.